Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: PHD Student
ORCID: 0000-0002-1464-9383
T +43 1 40400-58736
usevalad.ustsinau@meduniwien.ac.at
Keywords
Energy Metabolism; Multimodal Imaging; Obesity; Positron-Emission Tomography
Research group(s)
- Experimental Nuclear Medicine
Head: Cécile Philippe
Research Area: The research group "Experimental Nuclear Medicine" deals with the development and evaluation of radiotracers in various diseases. In addition, the group focuses on organ axes and pharmacokinetics.
Members:
Research interests
The primary focus of my research is centered around the evaluation of metabolic disorders. The role of energy metabolism in the development of various ailments, such as obesity, Type 2 Diabetes Mellitus, and Non-alcoholic Fatty Liver Disease (NAFLD), has been recently well-established. In this regard, I am interested in exploring the use of functional imaging techniques in nuclear medicine to detect variations in tracer kinetics in both clinical and preclinical models.
Techniques, methods & infrastructure
My expertise lies in managing the entire preclinical PET imaging process from start to finish. This includes producing radiotracers (labeling with 18F), handling animals safely with a FELASA certificate, establishing hybrid PET imaging protocols, and processing the resulting signal and images using software such as Pmod, Hermes, ITK Snap and others.
Selected publications
- Ustsinau, U. et al. (2023) ‘Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD’, Clinical Nutrition, 42(10), pp. 1839–1848. Available at: https://doi.org/10.1016/j.clnu.2023.08.001.
- Ustsinau, U. et al. (2024) ‘A Fully Automated Synthesis of 14-(R,S)-[18F]fluoro-6-thia-heptadecanoic Acid ([18F]FTHA) on the Elixys Radiosynthesizer’, Pharmaceuticals, 17(3), p. 318. Available at: https://doi.org/10.3390/ph17030318.